|Articles|September 29, 2021
Pharmacy Clinical Pearl of the Day: Signs and Symptoms of Bipolar Disorder
Author(s)Saro Arakelians, PharmD
There are several types of bipolar disorders, including mania or hypomania and depression.
Advertisement
Clinical Pearl of the Day: Signs and Symptoms of Bipolar Disorder
Bipolar disorder is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression).
Explanation:
- There are several types of bipolar disorders, including mania or hypomania and depression.
- Bipolar I disorder: At least 1 manic episode that may be preceded or followed by hypomanic or major depressive episodes. In some cases, mania may trigger a break from reality (psychosis).
- Bipolar II disorder: At least 1 major depressive episode and at least 1 hypomanic episode, but no manic episodes.
- Cyclothymic disorder: At least 2 years—or 1 year in children and teenagers—of many periods of hypomania symptoms and periods of depressive symptoms.
- Treatment options: May include mood stabilizers such as lithium, valproic acid, divalproex sodium, carbamazepine, and lamotrigine; antipsychotics such as olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and lurasidone; antidepressants and their combination with antipsychotics, such as Symbyax; and anti-anxiety medications, such as benzodiazepines.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5